1st Counsel – Lifestyle
Author:
Galimedix Therapeutics, Inc.
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
March 20, 2026
Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation
March 12, 2026
Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PD™ 2026 Conference
March 5, 2026